HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

@inproceedings{Press2016HER2GA,
  title={HER2 Gene Amplification Testing by Fluorescent In Situ
Hybridization (FISH): Comparison of the ASCO-College of American Pathologists
Guidelines With FISH Scores Used for Enrollment in Breast Cancer International
Research Group Clinical Trials},
  author={Michael F Press and Guido Sauter and Marc Buyse and H{\'e}l{\`e}ne Fourmanoir and Emmanuel Quinaux and Denice D. Tsao-Wei and Wolfgang Eiermann and Nicholas Robert and Tadeusz Pieńkowski and John Crown and Miguel Martin and Vicente Valero and John R. Mackey and Valerie B{\'e}e and Yanling Ma and Ivonne E. Villalobos and Anaamika Campeau and Martina Mirlacher and M. Lindsay and Dennis J Slamon},
  booktitle={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016}
}
Purpose ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the evaluation of human epidermal growth factor receptor 2 gene (HER2) amplification by fluorescent in situ hybridization (FISH). We retrospectively assessed the impact of these new guidelines by using annotated Breast Cancer International Research Group (BCIRG) -005, BCIRG-006, and BCIRG-007 clinical trials data for which we have detailed outcomes. Patients and Methods The HER2 FISH status… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Similar Papers

Loading similar papers…